在酸性鞘磷脂酶缺乏症中,模拟载脂蛋白纳米盘可减少脂质积聚并改善肝功能。

IF 4.2 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Troy A. Halseth PhD , Adele B. Correia BS , Mark L. Schultz PhD , Maria V. Fawaz PhD , Esmée Q. Kuiper BS , Preethi Kumaran BS , Kristen Hong Dorsey MS , Edward H. Schuchman PhD , Andrew P. Lieberman MD,PhD , Anna Schwendeman PhD
{"title":"在酸性鞘磷脂酶缺乏症中,模拟载脂蛋白纳米盘可减少脂质积聚并改善肝功能。","authors":"Troy A. Halseth PhD ,&nbsp;Adele B. Correia BS ,&nbsp;Mark L. Schultz PhD ,&nbsp;Maria V. Fawaz PhD ,&nbsp;Esmée Q. Kuiper BS ,&nbsp;Preethi Kumaran BS ,&nbsp;Kristen Hong Dorsey MS ,&nbsp;Edward H. Schuchman PhD ,&nbsp;Andrew P. Lieberman MD,PhD ,&nbsp;Anna Schwendeman PhD","doi":"10.1016/j.nano.2023.102705","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Acid sphingomyelinase deficiency (ASMD) is a severe </span>lipid<span> storage disorder caused by the diminished activity of the acid sphingomyelinase enzyme. ASMD is characterized by the accumulation of </span></span>sphingomyelin<span> in late endosomes and lysosomes<span><span> leading to progressive neurological dysfunction and hepatosplenomegaly<span>. Our objective was to investigate the utility of synthetic apolipoprotein A-I (ApoA-I) mimetics designed to act as lipid scavengers for the </span></span>treatment<span><span> of ASMD. We determined the lead peptide, 22A, could reduce sphingomyelin accumulation in ASMD patient skin fibroblasts<span> in a dose dependent manner. Intraperitoneal administration of 22A formulated as a synthetic high-density lipoprotein (sHDL) </span></span>nanodisc mobilized sphingomyelin from peripheral tissues into circulation and improved liver function in a mouse model of ASMD. Together, our data demonstrates that apolipoprotein mimetics could serve as a novel therapeutic strategy for modulating the pathology observed in ASMD.</span></span></span></p></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Apolipoprotein-mimetic nanodiscs reduce lipid accumulation and improve liver function in acid sphingomyelinase deficiency\",\"authors\":\"Troy A. Halseth PhD ,&nbsp;Adele B. Correia BS ,&nbsp;Mark L. Schultz PhD ,&nbsp;Maria V. Fawaz PhD ,&nbsp;Esmée Q. Kuiper BS ,&nbsp;Preethi Kumaran BS ,&nbsp;Kristen Hong Dorsey MS ,&nbsp;Edward H. Schuchman PhD ,&nbsp;Andrew P. Lieberman MD,PhD ,&nbsp;Anna Schwendeman PhD\",\"doi\":\"10.1016/j.nano.2023.102705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Acid sphingomyelinase deficiency (ASMD) is a severe </span>lipid<span> storage disorder caused by the diminished activity of the acid sphingomyelinase enzyme. ASMD is characterized by the accumulation of </span></span>sphingomyelin<span> in late endosomes and lysosomes<span><span> leading to progressive neurological dysfunction and hepatosplenomegaly<span>. Our objective was to investigate the utility of synthetic apolipoprotein A-I (ApoA-I) mimetics designed to act as lipid scavengers for the </span></span>treatment<span><span> of ASMD. We determined the lead peptide, 22A, could reduce sphingomyelin accumulation in ASMD patient skin fibroblasts<span> in a dose dependent manner. Intraperitoneal administration of 22A formulated as a synthetic high-density lipoprotein (sHDL) </span></span>nanodisc mobilized sphingomyelin from peripheral tissues into circulation and improved liver function in a mouse model of ASMD. Together, our data demonstrates that apolipoprotein mimetics could serve as a novel therapeutic strategy for modulating the pathology observed in ASMD.</span></span></span></p></div>\",\"PeriodicalId\":19050,\"journal\":{\"name\":\"Nanomedicine : nanotechnology, biology, and medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine : nanotechnology, biology, and medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1549963423000564\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine : nanotechnology, biology, and medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963423000564","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

酸性鞘磷脂酶缺乏症(ASMD)是一种严重的脂质储存障碍,由酸性鞘磷脂蛋白酶活性降低引起。ASMD的特征是鞘磷脂在晚期内体和溶酶体中积聚,导致进行性神经功能障碍和肝脾肿大。我们的目的是研究设计用作脂质清除剂的合成载脂蛋白A-I(ApoA-I)模拟物在治疗ASMD中的效用。我们确定,先导肽22A可以以剂量依赖的方式减少ASMD患者皮肤成纤维细胞中鞘磷脂的积累。在ASMD小鼠模型中,腹膜内施用配制为合成高密度脂蛋白(sHDL)纳米盘的22A将鞘磷脂从外周组织动员到循环中,并改善肝功能。总之,我们的数据表明,载脂蛋白模拟物可以作为一种新的治疗策略来调节ASMD中观察到的病理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Apolipoprotein-mimetic nanodiscs reduce lipid accumulation and improve liver function in acid sphingomyelinase deficiency

Apolipoprotein-mimetic nanodiscs reduce lipid accumulation and improve liver function in acid sphingomyelinase deficiency

Acid sphingomyelinase deficiency (ASMD) is a severe lipid storage disorder caused by the diminished activity of the acid sphingomyelinase enzyme. ASMD is characterized by the accumulation of sphingomyelin in late endosomes and lysosomes leading to progressive neurological dysfunction and hepatosplenomegaly. Our objective was to investigate the utility of synthetic apolipoprotein A-I (ApoA-I) mimetics designed to act as lipid scavengers for the treatment of ASMD. We determined the lead peptide, 22A, could reduce sphingomyelin accumulation in ASMD patient skin fibroblasts in a dose dependent manner. Intraperitoneal administration of 22A formulated as a synthetic high-density lipoprotein (sHDL) nanodisc mobilized sphingomyelin from peripheral tissues into circulation and improved liver function in a mouse model of ASMD. Together, our data demonstrates that apolipoprotein mimetics could serve as a novel therapeutic strategy for modulating the pathology observed in ASMD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.10
自引率
0.00%
发文量
133
审稿时长
42 days
期刊介绍: The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine. Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信